LUPIN.BO and LUPIN.NS Related Headlines
Go Back- Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
- Lupin presents phase 1 data for cancer drug LNP8701 at ASCO meeting
- Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
- Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
- Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
- Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
- Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
- Lupin completes acquisition of European eye care company VISUfarma
- Lupin Completes Acquisition of VISUfarma
- Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
- Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
- Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States
- 'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
- Lupin Launches Dasatinib Tablets in the United States
- Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
- Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin's New Corporate Offices in Bridgewater
- Lupin to present phase 1 data on cancer drug at ESMO congress
- Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
- Lupin launches partnership program for long-acting injectable platform
- Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
- Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare Syste
- Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
- Lupin gets FDA approval for risperidone injection with exclusivity
- Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
LUPIN.BO and LUPIN.NS Related Press Releases
Go Back- Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
- Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
- Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
- Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
- Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
- Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
- Lupin Completes Acquisition of VISUfarma
- Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
- Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
- Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States
- 'Made in India - The story of Desh Bandhu Gupta, Lupin and Indian Pharma' Book Launched in Mumbai
- Lupin Launches Dasatinib Tablets in the United States
- Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
- Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin's New Corporate Offices in Bridgewater
- Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
- Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
- Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare Syste
- Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
- Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
